Tasonermin - Genentech/Boehringer Ingelheim

Drug Profile

Tasonermin - Genentech/Boehringer Ingelheim

Alternative Names: Beromun; FK 516; TNF alpha - Genentech/Boehringer Ingelheim; TNF alpha-1a - Genentech/Boehringer Ingelheim; Tumour necrosis factor alpha - Genentech/Boehringer Ingelheim

Latest Information Update: 11 Jun 2015

Price : $50

At a glance

  • Originator Genentech
  • Developer Amarillo Biosciences; Asahi Kasei; Genentech; Hayashibara
  • Class Antineoplastics; Blood proteins; Glycoproteins; Monokines; Tumour necrosis factors
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sarcoma
  • Preregistration Submission Withdrawal Cancer
  • No development reported Viral infections

Most Recent Events

  • 11 Jun 2015 Launched for Sarcoma in Latvia, Lithuania, Luxembourg, Slovakia, Croatia, Estonia, Austria, Finland, France, Hungary, Malta, Romania and Slovenia (IV) before June 2015
  • 04 Oct 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 20 Jan 2000 Mochida has withdrawn the NDA for TNFα in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top